相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Empagliflozin protects against renal ischemia/reperfusion injury in mice
Qifeng Wang et al.
SCIENTIFIC REPORTS (2022)
SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease
Yong-Ping Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Muthiah Vaduganathan et al.
LANCET (2022)
The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
Saverio Muscoli et al.
PHARMACEUTICS (2022)
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Francesca Romana Prandi et al.
BIOMOLECULES (2022)
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
Coenraad Withaar et al.
CARDIOVASCULAR RESEARCH (2021)
Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists
Massimo Volpe et al.
CARDIOVASCULAR RESEARCH (2021)
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study
Jonas Oldgren et al.
DIABETES OBESITY & METABOLISM (2021)
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Scott D. Solomon et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Sabine Kahl et al.
DIABETES CARE (2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer et al.
CIRCULATION (2020)
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
Alexander J. M. Brown et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies
Afnan S. Alshnbari et al.
DIABETES THERAPY (2020)
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure The Need for Further Evidence Generation and Practice Guidelines Optimization
Muhammad Shahzeb Khan et al.
CIRCULATION (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
Skander Mulder et al.
DIABETES OBESITY & METABOLISM (2019)
Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators
Robyn Bruen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
Christian Anholm et al.
ATHEROSCLEROSIS (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets
Jens van de Wouw et al.
FRONTIERS IN PHYSIOLOGY (2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendan L. Neuen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Coronary Microvascular Dysfunction Is Associated With Myocardial Ischemia and Abnormal Coronary Perfusion During Exercise
Haseeb Rahman et al.
CIRCULATION (2019)
The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke
Xiaoyan Yang et al.
NEUROPHARMACOLOGY (2019)
SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Carolyn S. P. Lam et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Heart Failure in Type 2 Diabetes Mellitus Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies
Helena C. Kenny et al.
CIRCULATION RESEARCH (2019)
Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction
Masaru Obokata et al.
EUROPEAN HEART JOURNAL (2019)
Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis
Wei Chang et al.
MOLECULAR IMMUNOLOGY (2019)
Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?
Islam Y. Elgendy et al.
AMERICAN JOURNAL OF MEDICINE (2019)
Association of fasting glucagon-like peptide-1 with oxidative stress and subclinical atherosclerosis in type 2 diabetes
Hesham Alharby et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2019)
Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
Yu Ho Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure Insights From the Get With The Guidelines-Heart Failure Registry
Abhinav Sharma et al.
CIRCULATION-HEART FAILURE (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease
Menno Pruijm et al.
KIDNEY INTERNATIONAL (2018)
Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications
Martin A. Alpert et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2018)
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W. Mahaffey et al.
CIRCULATION (2018)
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Thomas A. Zelniker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Cardiovascular safety and benefits of GLP-1 receptor agonists
Niels B. Dalsgaard et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Vance B. Matthews et al.
JOURNAL OF HYPERTENSION (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide Causes Large and Rapid Epicardial Fat Reduction
Gianluca Iacobellis et al.
OBESITY (2017)
Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
Cristina Barale et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Renal glucose metabolism in normal physiological conditions and in diabetes
Mazen Alsahli et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits
Mitsumasa Sudo et al.
ATHEROSCLEROSIS (2017)
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction
Masaru Obokata et al.
CIRCULATION (2017)
Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice
Teruo Jojima et al.
ATHEROSCLEROSIS (2017)
Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition
S. P. Rajeev et al.
DIABETES OBESITY & METABOLISM (2016)
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
Manfredi Rizzo et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
Hiroaki Kusaka et al.
CARDIOVASCULAR DIABETOLOGY (2016)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation
Jozine M. ter Maaten et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
Isabelle Johansson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
Yumiko Chiba et al.
PLOS ONE (2016)
Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals
Tsutomu Hirano et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
Rohan Samson et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review
Carolyn L. Lekavich et al.
HEART FAILURE REVIEWS (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
Alessandra Dei Cas et al.
JACC-HEART FAILURE (2015)
Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Sanjiv J. Shah et al.
CIRCULATION (2015)
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Francisco Kerr Saraiva et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Cardiovascular Actions of Incretin-Based Therapies
John R. Ussher et al.
CIRCULATION RESEARCH (2014)
Molecular mechanisms of diabetic cardiomyopathy
Heiko Bugger et al.
DIABETOLOGIA (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Clinical Trials in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction
John G. F. Cleland et al.
HEART FAILURE CLINICS (2014)
Obesity, Subclinical Myocardial Injury, and Incident Heart Failure
Chiadi E. Ndumele et al.
JACC-HEART FAILURE (2014)
Contemporary Trends in Heart Failure With Reduced and Preserved Ejection Fraction After Myocardial Infarction: A Community Study
Yariv Gerber et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe-/- mice
Mathias Burgmaier et al.
ATHEROSCLEROSIS (2013)
Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation
Yao Dai et al.
CARDIOVASCULAR DRUGS AND THERAPY (2013)
Heart failure with preserved and reduced ejection fraction: different risk profiles for different diseases
Barry A. Borlaug
EUROPEAN HEART JOURNAL (2013)
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND
Frank P. Brouwers et al.
EUROPEAN HEART JOURNAL (2013)
Association Between Cardiovascular Autonomic Neuropathy and Left Ventricular Dysfunction DCCT/EDIC Study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications)
Rodica Pop-Busui et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen (Jim) Liu et al.
DIABETES (2012)
Kidney in Diabetes: from Organ Damage Target to Therapeutic Target
Teresa Salvatore et al.
CURRENT DRUG METABOLISM (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Effect of Obesity and Overweight on Left Ventricular Diastolic Function A Community-Based Study in an Elderly Cohort
Cesare Russo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Evolving focus on diastolic dysfunction in patients with coronary artery disease
Takahiro Ohara et al.
CURRENT OPINION IN CARDIOLOGY (2010)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Kausik K. Ray et al.
LANCET (2009)
Comparison or cardiac structural and functional changes in obese otherwise healthy adults with versus without obstructive sleep apnea
Maria E. Otto et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Outcome of heart failure with preserved ejection fraction in a population-based study
R. Sacha Bhatia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trends in prevalence and outcome of heart failure with preserved ejection fraction
Theophilus E. Owan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction - Results of the new York Heart Failure Registry
M Klapholz et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Sympathetic dysfunction in type 1 diabetes - Association with impaired myocardial blood flow reserve and diastolic dysfunction
R Pop-Busui et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Alterations of left ventricular myocardial characteristics associated with obesity
CY Wong et al.
CIRCULATION (2004)
Measures of obesity are associated with vascular stiffness in young and older adults
RP Wildman et al.
HYPERTENSION (2003)
Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction
JWH Fung et al.
CHEST (2002)
Heart failure with a normal ejection fraction - Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?
MR Zile et al.
CIRCULATION (2001)
Load versus humoral activation in the genesis of early hypertensive heart disease
CYT Hart et al.
CIRCULATION (2001)
Importance of heart failure with preserved systolic function in patients ≥65 years at age
DW Kitzman et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
分享论文
